The present invention relates to a combination of two or moreSomatostatin (SRIF) peptidomimetics (also referred to as Somatostatin- orSRIF-analogs) which have different selectivity for the human somatostatinreceptorsubtypes SSTR2 and SSTR5, the use of such combination in the treatment of adisease mediated by activation of somatostatin receptors (SSTR1-5), and topharmaceutical compositions comprising such a combination.